Latest News

Gene Therapy Multi Dose Clinical Trial Update

Gene Therapy Multi-Dose Clinical Trial Update: As you will know we had hoped to announce the outcome of the Multidose Gene Therapy Trial at the upcoming North American CF Conference (NACFC).

2 years ago



New Publication, Davies et al., 2014

Lee Davies evaluated a range of suitable, commercially available nebulisers for use in our clinical trial.

3 years ago



Ian Pringle Receives ASGCT Travel Grant Award

Consortium Scientist Dr Ian Pringle received a $500 award to attend this year's ASGCT Conference in Washington DC.

3 years ago



Young Investigator Award for Consortium PhD Student

Cathy Oliveira one of our PhD students at Oxford has received a Young Investigator Award to attend the 3rd Minicircle & DNA Vector Conference in Bielefeld, Germany, 8-9 May.

3 years ago



Hype Cycles and Technological Maturity - BSGCT Presentation

Natasha Davie, one of our PhD students in Oxford presented a different kind of poster at the 2014 British Society for Gene and Cell Therapy in London. Natasha is researching gene therapy as a whole and trying to gain an understanding as to why greater progress has not been made with this technology to date.

3 years ago



Wave II Update

Transcriptional control of transgene expression is crucial to successful gene therapy, yet few promoter/enhancer combinations have been tested in clinical trials. We created a simple, desktop computer database and populated it with promoter sequences from publicly available sources.

3 years ago



Clinical Trial Update

Clinical Trial Update. The Wave 1 Clinical Trial (CF gene delivered by liposomes) is going well. We were able to recruit all the patients needed from CF Centres across the UK. Approximately half the patients have received all the 12 doses of gene therapy or placebo given at monthly intervals.

3 years ago



Consortium scientists take part in CF Unite Event

Dr Uta Griesenbach & Dr Ian Pringle were in Nottingham today to take part in an event organised by CF Unite. Ian gave a presenation on CF Genes & Genetics and Uta talked about the ongoing work of the Consortium. Cystic Fibrosis Unite aims to bridge the gap between people with CF and the researchers investigating CF and how best to treat those with the condition. CFUnite has been created by people with CF, parents of children with CF, researchers and clinicians.

4 years ago



CF Trust Awards Consortium 300,000 for Wave II Research

The CF Trust has awarded the Consortium 308,000 towards our Wave II Lentiviral Research Programme.

4 years ago



Prof David Porteous OBE

Congratulations to Prof David Porteous who has been awarded an OBE for Services to Science.

4 years ago



New Publication, Pringle et al., 2012

New Consortium publication 'Rapid identification of novel functional promoters for gene therapy' is published in the Journal of Molecular Medicine. This paper results from a series of studies aiming to identify novel promoters for gene therapy. Promoters are vital to all gene therapy vectors as they are responsible for generating gene expression.

5 years ago



New Publication Describes Creation of pGM169

New Consortium publication 'CpG-free plasmid expression cassettes for cystic fibrosis gene therapy' is published in Biomaterials. This paper essentially describes the steps taken to optimise the design of the clinical trial plasmid.

5 years ago



New charity - Just Gene Therapy Launched to support the Consortium

We are pleased to announce the launch of new charity Just Gene Therapy with the specific aim of raising funds for gene therapy research for CF. The charity has been established by Rosie Barnes in conjunction with Professor Eric Alton, and is the only way in which donations can directly support the work of the Consortium.

5 years ago



Consortium Scientists Feature on BBC Radio 4 Programme

Eric Alton, Deborah Gill, Steve Hyde & Uta Griesenbach all took part in a BBC Radio 4 Documentary. The documentary described at length the work of the Consortium and can be listened to again via BBC iPlayer.

5 years ago



MHRA Approval for Multi-Dose Clinical Trial

Last week the MHRA (Medicines and Healthcare Products Regulatory Agency) granted the final approval necessary for the main body of work in our planned clinical trial to begin. With everything now in place, the first patient visits in London and Edinburgh will take place over the next week. Due to the number of patients enrolled and the 12 visits/patient over 12 months, the trial has a staggered start and finish and will run until sometime in the first half of 2014.

5 years ago




E.coli from a large scale industrial production of our clinical trial plasmid pGM169.


A frozen vial of GL67A (left) and a frozen vial of pGM169 plasmid DNA (right)


DNA fragments being cut from an agarose gel exposed to UV.


A pellet of E.coli containing a plasmid expressing a pink fluorescent protein.